Anti-NRP1/ BDCA4/ CD304 monoclonal antibody
Anti-NRP1/ BDCA4/ CD304 antibody for FACS & in-vivo assay
Go to NRP1/NRP1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T15023-Ab-1/ GM-Tg-hg-T15023-Ab-2 | Anti-Human NRP1 monoclonal antibody | Human |
GM-Tg-rg-T15023-Ab-1/ GM-Tg-rg-T15023-Ab-2 | Anti-Rat NRP1 monoclonal antibody | Rat |
GM-Tg-mg-T15023-Ab-1/ GM-Tg-mg-T15023-Ab-2 | Anti-Mouse NRP1 monoclonal antibody | Mouse |
GM-Tg-cynog-T15023-Ab-1/ GM-Tg-cynog-T15023-Ab-2 | Anti-Cynomolgus/ Rhesus macaque NRP1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T15023-Ab-1/ GM-Tg-felg-T15023-Ab-2 | Anti-Feline NRP1 monoclonal antibody | Feline |
GM-Tg-cang-T15023-Ab-1/ GM-Tg-cang-T15023-Ab-2 | Anti-Canine NRP1 monoclonal antibody | Canine |
GM-Tg-bovg-T15023-Ab-1/ GM-Tg-bovg-T15023-Ab-2 | Anti-Bovine NRP1 monoclonal antibody | Bovine |
GM-Tg-equg-T15023-Ab-1/ GM-Tg-equg-T15023-Ab-2 | Anti-Equine NRP1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T15023-Ab-1/ GM-Tg-hg-T15023-Ab-2; GM-Tg-rg-T15023-Ab-1/ GM-Tg-rg-T15023-Ab-2; GM-Tg-mg-T15023-Ab-1/ GM-Tg-mg-T15023-Ab-2; GM-Tg-cynog-T15023-Ab-1/ GM-Tg-cynog-T15023-Ab-2; GM-Tg-felg-T15023-Ab-1/ GM-Tg-felg-T15023-Ab-2; GM-Tg-cang-T15023-Ab-1/ GM-Tg-cang-T15023-Ab-2; GM-Tg-bovg-T15023-Ab-1/ GM-Tg-bovg-T15023-Ab-2; GM-Tg-equg-T15023-Ab-1/ GM-Tg-equg-T15023-Ab-2 |
Products Name | Anti-NRP1 monoclonal antibody |
Format | mab |
Target Name | NRP1 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-NRP1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Biosimilar | GMP-Bios-ab-618 | Pre-Made Vesencumab biosimilar, Whole mAb, Anti-NRP1 Antibody: Anti-BDCA4/CD304/NP1/NRP/VEGF165R therapeutic antibody |
Target Antigen | Products Developing | Multi-species NRP1/ BDCA4/ CD304 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMAP000141 | Human NRP1 Adenovirus plasmid |
ORF Viral Vector | vGMAP000141 | Human NRP1 Adenovirus particle |
Target information
Target ID | GM-T15023 |
Target Name | NRP1 |
Gene ID | 8829,18186,246331,697755,477955,101094027,539369,100060430 |
Gene Symbol and Synonyms | BDCA4,C530029I03,CD304,NP-1,NP1,NPN-1,Npn1,NRP,NRP1,VEGF165R |
Uniprot Accession | O14786,Q9QWJ9 |
Uniprot Entry Name | NRP1_HUMAN,NRP1_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, INN Index |
Disease | Cancer |
Gene Ensembl | ENSG00000099250 |
Target Classification | Tumor-associated antigen (TAA) |
The target: NRP1, gene name: NRP1, also named as BDCA4, CD304, NP1, NRP, VEGF165R. This gene encodes one of two neuropilins, which contain specific protein domains which allow them to participate in several different types of signaling pathways that control cell migration. Neuropilins contain a large N-terminal extracellular domain, made up of complement-binding, coagulation factor V/VIII, and meprin domains. These proteins also contains a short membrane-spanning domain and a small cytoplasmic domain. Neuropilins bind many ligands and various types of co-receptors; they affect cell survival, migration, and attraction. Some of the ligands and co-receptors bound by neuropilins are vascular endothelial growth factor (VEGF) and semaphorin family members. This protein has also been determined to act as a co-receptor for SARS-CoV-2 (which causes COVID-19) to infect host cells. [provided by RefSeq, Nov 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.